Armata Pharmaceuticals (ARMP) Cash from Investing Activities (2013 - 2026)

Armata Pharmaceuticals has reported Cash from Investing Activities for 14 years, with the latest figure at -$63000.0 in Q1 2026.

• Quarterly Cash from Investing Activities rose 36.36% year-over-year to -$63000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$506000.0 (up 70.72% YoY) and the FY2025 annual result came in at -$542000.0, up 71.15% from the prior year.
• Cash from Investing Activities slipped to -$63000.0 in Q1 2026 per ARMP's latest filing, from -$52000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $455000.0 in Q4 2022 and troughed at -$3.5 million in Q3 2023.
• A 5-year average of -$754647.1 and a median of -$242000.0 in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 299.56% in 2022, then slumped 751.69% in 2023.
• Over 5 years, Cash from Investing Activities stood at $455000.0 in 2022, then slumped by 625.27% to -$2.4 million in 2023, then jumped by 103.22% to $77000.0 in 2024, then tumbled by 167.53% to -$52000.0 in 2025, then retreated by 21.15% to -$63000.0 in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$63000.0, -$52000.0, and -$242000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.